Deborah Charles
Pain Medicine · Somersworth, NHNPI 1942661558
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,129, 7.1 times the $158 reported in 2021.
Across 155 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Valinor Pharma, LLC$531
- AbbVie$521
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$406
- Collegium Pharmaceutical, Inc.$264
- Boston Scientific$263
- Nevro Corp.$185
- plus $414 from 9 others
What the payments were for
- Food & beverage$2,585100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Valinor Pharma, LLC | 40 | $531 |
| AbbVie | 23 | $521 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 34 | $406 |
| Collegium Pharmaceutical, Inc. | 24 | $264 |
| Boston Scientific | 5 | $263 |
| Nevro Corp. | 11 | $185 |
| Pfizer | 6 | $151 |
| Teva Pharmaceuticals USA, Inc. | 5 | $89 |
| Painteq LLC | 1 | $46 |
| Lundbeck LLC | 1 | $31 |
| Averitas Pharma Inc. | 1 | $27 |
| IBSA Pharma Inc. | 1 | $24 |
| Novo Nordisk | 1 | $18 |
| Indivior Inc. | 1 | $15 |
| Amgen | 1 | $14 |
How this compares
$2,585 in reported general payments places this provider in the 55th percentile of 38 pain medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucyntaTapentadol Hcl | 69 | $100,753 |
| OxycontinOxycodone Hcl | 142 | $85,557 |
| BelbucaBuprenorphine Hcl | 119 | $84,309 |
| Xtampza ErOxycodone Myristate | 115 | $79,368 |
| Buprenorphine | 100 | $28,378 |
| Oxycodone Hcl | 1,099 | $28,160 |
| MovantikNaloxegol Oxalate | 31 | $17,402 |
| Nucynta ErTapentadol Hcl | 16 | $12,354 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 306 | $10,887 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $10,667 |
| Fentanyl | 52 | $10,396 |
| Hysingla ErHydrocodone Bitartrate | 26 | $10,322 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 291 | $8,941 |
| Morphine Sulfate ErMorphine Sulfate | 276 | $8,785 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 39 | $7,148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta, Belbuca, Xtampza Er, Nucynta Er | $264 | $276,784319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 38 pain medicine providers in New Hampshire.
Other pain medicine in Somersworth
- Daniel GraubertSomersworth$7K
- Praveen SuchdevNashua$72K
- Zubin BatlivalaBedford$18K
- Bert FichmanLebanon$15K
- Dennis ThapaDover$13K
- Michael BovaLebanon$12K
- James MirazitaNashua$10K
- Robert LehnPortsmouth$9K
- Thomas ZoukiDover$9K
- Edward DohertyNashua$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.